A Phase II Trial of COL-3 in Patients With HIV Related Kaposi's Sarcoma
Status:
Terminated
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
COL-3 may stop the growth of cancer by stopping blood flow to the tumor. Randomized phase II
trial to compare the effectiveness of two different regimens of COL-3 in treating patients
who have HIV-related Kaposi's sarcoma.